PRAIM: AI finds more breast cancers in German screening
In a prospective study of over 460,000 women at twelve German sites, AI-assisted reading detected 6.7 cancers per thousand exams versus 5.7 without AI. Recall rates for further assessment were 37.4 versus 38.3 per thousand. This observational study does not show a survival benefit, and estimates of workload reduction with automated reading come from simulations.
Technology: AI support for mammogram reading (Vara)
Publication: Publication status unspecified in annotation · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Not reported
- Test type: prospective or independent check
- Tested: A prospective study of over 460,000 women at twelve German sites (2021-2023) compared AI-assisted reading with standard double reading by radiologists: 6.7 vs 5.7 cancers per 1,000 exams.
- Still unknown: No survival benefit is shown; workload and skipped-review figures come from simulations, and the effect on prognosis is still to be studied.
- AI role: AI read about half of the mammograms, marking cases as normal or suspicious, with the rest read by double reading.
Evidence sources: https://www.uni-luebeck.de/aktuelles/pressemitteilung/artikel/ki-verbessert-brustkrebserkennung.html
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 280 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.